DiaSorin to acquire U.S.-based Luminex for around $1.8 billion

Dow Jones2021-04-12

Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. $(LMNX)$ for around $1.8 billion.

DiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. The price represents a 24% premium to Luminex's close on Feb. 24, the date prior to press speculation about a potential deal.

The deal is expected to close in the third quarter of 2021, pending regulatory approvals. Acquiring Luminex will boost DiaSorin's presence in molecular diagnostics, particularly in the "attractive and high growth syndromic multiplex panel testing market," said a team of Jefferies analysts led by Peter Welford, in a note to clients.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • tls
    2021-04-12
    tls
    Yes
发表看法
1